Article Dans Une Revue La Presse Médicale Année : 2024

Impact of thrombophilia on venous thromboembolism management

Résumé

Hypercoagulable states, also called thrombophilia, can either be congenital or acquired. Congenital thrombophilia, associated mainly with venous thrombosis, is either secondary to coagulation-inhibitor deficiencies, i.e., antithrombin, protein C and Protein S, or gain of function mutations, i.e., factor V Leiden and prothrombin G20210A mutations. Despite the relative frequency of these two mutations, they have not been associated with venous thrombosis recurrence. Most prevalent thrombophilia have a limited impact and usually does not change indications for duration of antithrombotic treatment or prophylaxis compared to decisions based on clinical factors. However, rare inherited thrombophilia such as antithrombin deficiency could justify a long-term anticoagulation. The main acquired thrombophilia, the Antiphospholipid syndrome (APS), is associated with both arterial and venous thrombosis. Its impact on patient management is significant: choice of the anticoagulant (DOAC vs. warfarin), duration of anticoagulation, screening of any organ involvement and systemic autoimmune disease, introduction of immunosuppressive therapy.

Fichier principal
Vignette du fichier
Emmerich et al. - 2024 - Impact of thrombophilia on venous thromboembolism .pdf (1.15 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-04717196 , version 1 (02-12-2024)

Licence

Identifiants

Citer

Joseph Emmerich, Stéphane Zuily, Isabelle Gouin-Thibault, Pierre-Emmanuel Morange, Francis Couturaud, et al.. Impact of thrombophilia on venous thromboembolism management. La Presse Médicale, 2024, 53 (4), pp.104247. ⟨10.1016/j.lpm.2024.104247⟩. ⟨hal-04717196⟩
485 Consultations
365 Téléchargements

Altmetric

Partager

  • More